Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GT 2331

Known as: GT-2331 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release… Expand
2006
2006
Histamine H(3) receptor antagonists are potential therapeutic agents for cognitive dysfunction, epilepsy, hypersomnia and obesity… Expand
2005
2005
Previously reported pharmacological studies using the imidazole-containing histamine H3 receptor ligands GT-2331 (Cipralisant… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
GT-2331 is a potent histamine H(3) antagonist which has entered clinical trials. Efficient multigram syntheses of this compound… Expand
Highly Cited
2002
Highly Cited
2002
Histamine H(3) receptor antagonists have been proposed as potentially useful therapeutic agents for the treatment of several… Expand
2002
2002
The selective H(3) receptor agonist (R)-alpha-methylhistamine [(R)-alpha-MeHA] stimulates drinking in the adult rat. In the… Expand
2000
2000
The histamine H3 receptor provides a negative feedback mechanism for the release and synthesis of histamine. On non-histaminergic… Expand
1999
1999
Previously, a novel series of 1H-4-substituted imidazole compounds were described as potent and selective histamine (HA) H3… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
1998
1998
GT-2227 (4-(6-cyclohexylhex-cis-3-enyl)imidazole) and GT-2331 ((1R,2R)-4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole) were… Expand